CAS 81403-68-1|Alfuzosin hydrochloride
Introduction：Basic information about CAS 81403-68-1|Alfuzosin hydrochloride, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Alfuzosin hydrochloride | ||
|---|---|---|---|
| CAS Number | 81403-68-1 | Molecular Weight | 425.910 |
| Density | 1.272 g/cm3 | Boiling Point | 687.7ºC at 760 mmHg |
| Molecular Formula | C19H28ClN5O4 | Melting Point | 225°C |
| MSDS | ChineseUSA | Flash Point | / |
| Symbol | GHS07 | Signal Word | Warning |
Names
| Name | alfuzosin hydrochloride |
|---|---|
| Synonym | More Synonyms |
Alfuzosin hydrochloride BiologicalActivity
| Description | Alfuzosin hydrochloride is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).Target: α1 adrenergic receptorAlfuzosin, a new quinazoline derivative, acts as a selective and competitive antagonist of alpha 1-adrenoceptor-mediated contraction of prostatic, prostatic capsule, bladder base and proximal urethral smooth muscle, thereby reducing the tone of these structures. Consequently, urethral pressure and resistance, bladder outlet resistance, bladder instability and symptoms associated with benign prostatic hyperplasia are reduced. A limited range of clinical studies have shown oral alfuzosin to be more effective than placebo (in studies of < or = 6 months duration), to have sustained effects on long term administration (< or = 30 months), and to be comparable with the alpha 1-adrenoceptor antagonist prazosin, in the symptomatic treatment of benign prostatic hyperplasia.Oral alfuzosin 7.5 to 10 mg/day in divided doses appears to be a promising first-line agent for symptomatic treatment of noncomplicated mild to moderate benign prostatic hyperplasia in patients with a high dynamic component to their obstruction. In addition, alfuzosin offers an alternative to prostatectomy (the current 'gold standard') in patients who require surgery but are unfit for this treatment, and in patients requiring symptomatic relief while awaiting surgery. |
|---|---|
| Related Catalog | Signaling Pathways >>GPCR/G Protein >>Adrenergic ReceptorNatural Products >>AlkaloidResearch Areas >>Endocrinology |
| References | [1]. Wilde MI, et al. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs. 1993 Mar;45(3):410-29. |
Chemical & Physical Properties
| Density | 1.272 g/cm3 |
|---|---|
| Boiling Point | 687.7ºC at 760 mmHg |
| Melting Point | 225°C |
| Molecular Formula | C19H28ClN5O4 |
| Molecular Weight | 425.910 |
| Exact Mass | 425.182983 |
| PSA | 111.83000 |
| LogP | 3.12480 |
| InChIKey | YTNKWDJILNVLGX-UHFFFAOYSA-N |
| SMILES | COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC.Cl |
| Storage condition | Store at RT |
Safety Information
| Symbol | GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302 |
| Precautionary Statements | P301 + P312 + P330 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xn |
| Risk Phrases | R22 |
| RIDADR | NONH for all modes of transport |
Articles2
More Articles| Comparison ofcore–shelland totally porous ultra high performance liquid chromatographic stationary phases based on their selectivity towards alfuzosin compounds J. Chromatogr. A. 1346 , 69-77, (2014) • KUL procedure was adapted to testing of UHPLC stationary phases. • Classification of core–shell and UHPLC columns was performed. • Verification of the KUL results was based on the separation of alfu... | |
| Temperature influencing permeation pattern of alfuzosin: an investigation using DoE. Medicina (Kaunas.) 51 , 253-61, (2015) There has been relatively little investigation of the effect of temperature on skin permeation compared to other methods of penetration enhancement. A principal physicochemical factor which controls t... |
Synonyms
| SL 77 499-10 |
| N-{3-[(4-amino-6,7-diméthoxyquinazolin-2-yl)(méthyl)amino]propyl}tétrahydrofurane-2-carboxamide chlorhydrate |
| Uroxatral |
| MFCD00879135 |
| N-{3-[(4-Amino-6,7-dimethoxy-2-quinazolinyl)(methyl)amino]propyl}tetrahydro-2-furancarboxamide hydrochloride (1:1) |
| 2-furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-, monohydrochloride |
| Alfuzosin HCl |
| N-{3-[(4-Amino-6,7-dimethoxychinazolin-2-yl)(methyl)amino]propyl}tetrahydrofuran-2-carboxamidhydrochlorid |
| 2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-, hydrochloride (1:1) |
| SL 77-499-10 |
| Alfuzosin hydrochloride |
| N-{3-[(4-Amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}tetrahydrofuran-2-carboxamide hydrochloride (1:1) |
| Alfuzosin (hydrochloride) |
